Vyleesi® product results: 14% growth in prescriptions dispensed over prior quarter – 7 consecutive quarters of double digit growth. Click here to learn more ›

Phase 1 Study of the Novel A-Type Natriuretic Receptor Agonist, PL-3994, in Healthy Volunteers

Leave a Reply

Scroll to Top